Blaurock Markus, Brunner Cornelia, Busch Chia-Jung
Klinik für Hals‑, Nasen‑, Ohrenkrankheiten, Kopf- und Halschirurgie, Universitätsmedizin Greifswald, Ferdinand Sauerbruch Straße, 17475, Greifswald, Deutschland.
Klinik für Hals‑, Nasen‑, Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsklinikum Ulm, Ulm, Deutschland.
HNO. 2024 Dec;72(12):857-861. doi: 10.1007/s00106-024-01523-x. Epub 2024 Nov 5.
Systemic therapy of head and neck squamous cell carcinoma (HNSCC), in contrast to local therapy, is a very general term for the use of drugs that affect the entire organism. Immunotherapy is a subtype of systemic therapy, although the boundaries are hard to define, since the immune system is likely to play an essential role in all treatments. This article focuses on systemic therapy.
All abstracts and presentations on systemic therapy of HNSCC from the American Society of Clinical Oncology (ASCO) 2024 annual congress were assessed for relevance. The main contributions were reviewed and summarized.
For the first time, a randomized trial demonstrated a survival advantage for systemic therapy in patients with a poor performance status over best supportive care (BSC). Clinical studies using antibody-drug conjugates (ADCs) show a promising response. In addition, the neoadjuvant approach was resumed through various study approaches.
Even in patients with a reduced general condition, systemic therapy can lead to a substantial improvement in overall survival. The systemic therapy approach remains exciting for HNSCC, with new substances and areas of application not only in the palliative situation.
与局部治疗相比，头颈部鳞状细胞癌（HNSCC）的全身治疗是一个非常宽泛的术语，指使用影响整个机体的药物。免疫治疗是全身治疗的一种亚型，尽管其界限难以界定，因为免疫系统可能在所有治疗中都发挥着重要作用。本文聚焦于全身治疗。
对美国临床肿瘤学会（ASCO）2024年年会中所有关于HNSCC全身治疗的摘要和报告进行相关性评估。对主要贡献进行了回顾和总结。
一项随机试验首次证明，对于身体状况较差的患者，全身治疗相较于最佳支持治疗（BSC）具有生存优势。使用抗体药物偶联物（ADC）的临床研究显示出有前景的反应。此外，通过各种研究方法恢复了新辅助治疗方法。
即使是一般状况较差的患者，全身治疗也能显著改善总生存期。全身治疗方法对HNSCC仍然令人兴奋，不仅在姑息治疗方面有新的药物和应用领域。
